Skip to main content

Table 1 Patient and disease characteristics at start of etanercept therapy a

From: Automated determination of bone age and bone mineral density in patients with juvenile idiopathic arthritis: a feasibility study

Baseline characteristics N = 67 patients
Females, n (%) 36 (54)
Age at onset JIA in years, mean (±SD) 8.5 (±3.8)
Age at start etanercept in years, mean (±SD) 11.0 (±3.1)
JIA disease duration before start etanercept in years, median (IQR) 1.8 (1.1 to 3.8)
ANA-positive, n (%) 14 (21)
Category JIA, n (%)  
Systemic JIA 4 (6)
Polyarticular RF-negative 27 (40)
Polyarticular RF-positive 9 (13)
Oligoarticular extended 18 (27)
Psoriatic arthritis 5 (8)
Enthesitis-related arthritis 4 (6)
Previously used medications, n (%)  
Systemic prednisone 32 (48)
Methotrexate 66 (99)
DMARD other than MTX 14 (21)
Concomitant comedication at start of biologic therapy, n (%)  
Systemic prednisone 26 (39)
Methotrexate 64 (96)
DMARD other than MTX 2 (3)
Disease activity parameters at baseline, median (IQR)  
Physician-rated VAS (0 to 10 cm; best score = 0) 6.5 (5.0 to 7.4)
CHAQ total (0 to 3; best score = 0) 1.50 (0.90 to 2.10)
VAS pain (0 to 10 cm; best score = 0) 6.3 (2.4 to 7.7)
VAS well-being (0 to 10 cm; best score = 0) 6.1 (3.2 to 7.4)
Active joints 11 (7 to 18)
Limited joints 6 (3 to 13)
ESR 11 (5 to 29)
JADAS-10 (0 to 40), mean (±SD) 21 (±5)
Ever hand or wrist involvement, n (%) 64 (96)
Z-score of BA, mean (±SD) -0.36 (±1.44)
Z-score of BHI, mean (±SD) -0.85 (±1.15)b
  1. aANA, Antinuclear antibody; BA, Bone age; BHI, Bone Health Index; CHAQ, Child Health Assessment Questionnaire; DMARD, Disease-modifying antirheumatic drug; ESR, Erythrocyte sedimentation rate; JADAS, Juvenile Arthritis Disease Activity Score; JIA, Juvenile idiopathic arthritis; MTX, Methotrexate; RF, Rheumatoid factor; VAS, Visual analogue scale; Z-score, Standard deviation compared with healthy population. bSignificantly different from 0 at the P < 0.05 level.